Bio-Rad Laboratories ddPLEX ESR1 Mutation Detection Kit

Bio-Rad Laboratories has launched the ddPLEX ESR1 Mutation Detection Kit, an ultrasensitive multiplexed digital PCR assay. The assay expands the company’s Droplet Digital PCR (ddPCR) offering for the oncology market, where highly sensitive and multiplexed mutation detection assays aid translational research, therapy selection and disease monitoring.

The kit enables simultaneous detection, discrimination and absolute quantification of seven known relevant ESR1 mutations in a single well, with an analytical sensitivity down to 0.01% variant allele fraction (VAF). It includes controls and enables same-day results from either circulating tumour DNA (ctDNA) from plasma or DNA from formalin-fixed paraffin-embedded (FFPE) tissue samples.

The research-use assay is developed for Bio-Rad’s QX600 Droplet Digital PCR System, which brings advanced multiplexing and high sensitivity to a simple workflow with powerful data analysis. The assay is also the first to license NuProbe’s allele enrichment technology, announced by the two companies in 2022.